Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Leap Therapeutics (LPTX – Research Report) today and set a price target of $6.00. The company’s shares closed last Friday at $1.20, close to its 52-week low of $0.92.
According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.7% and a 33.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.
Currently, the analyst consensus on Leap Therapeutics is a Moderate Buy with an average price target of $6.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.17 and a one-year low of $0.92. Currently, Leap Therapeutics has an average volume of 769.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Read More on LPTX:
